4//SEC Filing
Bermingham Nessan 4
Accession 0001209191-17-064786
CIK 0001652130other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 5:27 PM ET
Size
13.1 KB
Accession
0001209191-17-064786
Insider Transaction Report
Form 4
Bermingham Nessan
DirectorPresident & CEO10% Owner
Transactions
- Sale
Common Stock
2017-12-07$21.05/sh−103,574$2,180,378→ 579,959 total - Sale
Common Stock
2017-12-06$20.28/sh−99,033$2,008,191→ 696,000 total - Sale
Common Stock
2017-12-06$20.84/sh−12,467$259,810→ 683,533 total - Sale
Common Stock
2017-12-07$21.46/sh−27,566$591,489→ 552,393 total - Sale
Common Stock
2017-12-08$20.82/sh−94,143$1,960,151→ 458,250 total
Footnotes (5)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $19.70 to $20.69. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.70 to $21.12. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F3]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.33 to $21.32. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F4]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $21.33 to $21.65. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F5]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.51 to $21.48. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
Documents
Issuer
Intellia Therapeutics, Inc.
CIK 0001652130
Entity typeother
Related Parties
1- filerCIK 0001377759
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 5:27 PM ET
- Size
- 13.1 KB